Ascletis Raises Mammoth $100 Million To Deploy Its US-China Hybrid Model
This article was originally published in Start Up
Executive Summary
In the latest and most ambitious attempt to create a new global pharma with one foot in China and one in the West, Ascletis Inc. has launched with a hybrid drug development model that has attracted $100 million in committed funding.